Pfizer hiring 40 at its Lipitor and Viagra API plants in Ireland

By Dan Stanton

- Last updated on GMT

Pfizer's blockbuster anti-cholesterol drug Lipitor is made at the Little Island plant in Cork, Ireland. Lipitor came off patent in 2011.
Pfizer's blockbuster anti-cholesterol drug Lipitor is made at the Little Island plant in Cork, Ireland. Lipitor came off patent in 2011.
Over 40 new jobs will be created at Pfizer’s manufacturing sites in Cork, Ireland, including at a bulk Lipitor facility once earmarked for closure.

Annual revenues from Lipitor reached over $12bn (€10.5bn) worldwide​ in the mid-2000s, but following its loss of exclusivity in November 2011 and the subsequent drop in sales, Pfizer announced it was selling the site in Cork, Ireland​ which makes the API for the anti-cholesterol drug.

But a U-turn earlier this year brought some relief to the 160 staff employed at Little Island and today’s announcement that Pfizer is adding jobs across its two plants in Cork should bring further reassurance.

Throughout 2015/2016 the Little Island and Ringaskiddy sites will be boosted by a total of 40 new jobs across a wide range of areas including Process Operators, Mechanical & Electrical/ Instrumentation Craft, Process Engineers, Process Chemists, and Quality Control Analysts.

We are delighted to announce the news Pfizer is hiring,”​ said Seamus Fives, site Lead at the two plants.

“These are key roles within the organisation and play an important function in the manufacturing and delivery of medicines to patients worldwide.”

CVs accepted

Applications are now open but if you are interested you better be quick, as Pfizer says the closing date is October 16.

Pfizer chose to retain the Little Island plant in March​, after the firm saw an increase demand for its one-time blockbuster.

The facility is also manufacturing Pfizer’s newest small molecule cancer medicines, Spokesperson Karen O’Keefe told this publication today, and is benefitting from a $30m investment last year in a New Product Technology Laboratory (NPTL) at the Ringaskiddy plant – a site which also avoided closure following surprising post-expiration sales of erectile dysfunction drug Viagra

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars